Macrogen

Macrogen FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Macrogen (038290.KQ) as of Oct 28, 2026 is -674.57 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 373.05 % — a change of -280.83% (lower).

FCF Conversion

-674.57 %

YoY

-280.83%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Macrogen is 2025 -674.57 % . FCF Conversion Rate (FCF/EBITDA) of Macrogen was 2024 373.05 % . It decreases by -280.83% lower compared to the previous year.

The Macrogen FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
317.20 KRW
Jan 1, 2019
1,370.83 KRW
Jan 1, 2020
2.40 KRW
Jan 1, 2021
1,042.91 KRW
Jan 1, 2022
40.52 KRW
Jan 1, 2023
116.46 KRW
Jan 1, 2024
373.05 KRW
Jan 1, 2025
-674.57 KRW
The Macrogen FCF Conversion history
YEARFCF ConversionYoY
-674.57 %-280.83%
373.05 %+220.32%
116.46 %+187.42%
40.52 %-96.11%
1,042.91 %+43,421.33%
2.40 %-99.83%
1,370.83 %+332.17%
317.20 %+1,517.24%
19.61 %-86.75%
148.01 %-673.09%
-25.83 %-95.05%
-521.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Macrogen Stock analysis

What does Macrogen do? Macrogen Inc. generates revenue through its four business divisions. The DNA sequencing division provides genome sequencing analysis services to clients requiring genetic data processing. The DNA chips division sells products including Illumina chips, MacArray chips, and customized chips to research institutions and biotech firms. The transgenic and knockout mouse division offers gene engineering services to pharmaceutical companies and academic laboratories. The oligonucleotide DNA division supplies oligonucleotide DNA manufacturing services to biotechnology clients. All services are delivered domestically and internationally to established market segments. The company's DNA chips division markets specific branded products like Illumina chips and MacArray chips, which are purchased by research organizations and biotechnology enterprises. Gene engineering services from the transgenic division are bought by pharmaceutical companies seeking to develop new treatments. Oligonucleotide DNA manufacturing services target biotech clients needing specialized DNA synthesis. Domestic and overseas markets represent the primary customer segments for all divisions. Macrogen's product portfolio includes DNA sequencing services, DNA chip products, gene engineering solutions, and oligonucleotide DNA manufacturing. Clients include research institutions, pharmaceutical companies, academic laboratories, and biotechnology firms. The DNA chips division's branded products are specifically named in the description, while other services are described by their technical functions. Market segments are defined by the company's domestic and international operations. Macrogen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Macrogen stock

FCF Conversion Rate (FCF/EBITDA) of Macrogen is -674.57 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Macrogen changed from 373.05 % to -674.57 %, representing a -280.83% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Macrogen since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Macrogen with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Macrogen

All Key Metrics — Macrogen